David Baratz is a Respiratory physician affiliated with Gossamer Bio. OpenAlex indexes 11 publications with 249 citations (h-index 3); ClinicalTrials.gov lists 1 registered study matched to this name.
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
3811 E Bell Rd Ste 107
Phoenix, AZ 850322158
Telephone
602-340-1689Provider last certified this registry record 7 Oct 2025.
Clinical trials
Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.
Industry payments
57 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- AstraZeneca Pharmaceuticals LPProgram year202526 payments
- GlaxoSmithKline, LLC.Program year202532 payments
- Actelion Pharmaceuticals US, Inc.Program year202513 payments
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Respiratory
63.1%beta2-Adrenergic Agonist27.9%Albuterol Sulfate Hfa95%Ventolin Hfa5%Part D≥411 patientsCorticosteroid24%Trelegy Ellipta46%Breztri Aerosphere21%Symbicort10%Breo Ellipta9%Fluticasone Propionate5%Arnuity Ellipta3%Breyna3%Budesonide-Formoterol Fumarate2%Dulera1%Part D<11 patients+ 5 more classes in this area
Nervous system
12.1%Benzodiazepine2.7%Clonazepam41%Alprazolam31%Lorazepam15%Triazolam13%Part D<11 patientsCentral Nervous System Stimulant2.6%Dextroamphetamine-Amphetamine41%Dextroamphetamine-Amphet Er31%Methylphenidate Hcl29%Part D<11 patients+ 9 more classes in this area
Cardiovascular
8.9%Endothelin Receptor Antagonist5.1%Opsumit83%Ambrisentan11%Letairis6%Part D<11 patientsSoluble Guanylate Cyclase Stimulator2.1%Adempas100%Part D<11 patients+ 3 more classes in this area
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- Seralutinib in adults with pulmonary arterial hypertension (TORREY): a randomised, double-blind, placebo-controlled phase 2 trial
The Lancet Respiratory Medicine
2024 - A Phase I Study of TRK-250, a Novel siRNA-Based Oligonucleotide, in Patients with Idiopathic Pulmonary Fibrosis
Journal of Aerosol Medicine and Pulmonary Drug Delivery
2023 - January 2023 Sleep Case of the Month: An Unexpected EEG Abnormality
Southwest Journal of Pulmonary Critical Care & Sleep
2023 - Correct Scoring of Hypopneas in Obstructive Sleep Apnea Reduces Cardiovascular Morbidity
Southwest Journal of Pulmonary and Critical Care
2020 - September 2015 puilmonary case of the month: holy smoke
Southwest Journal of Pulmonary and Critical Care
2015
Similar KOLs
Other experts from the same institution or the same specialty.
Tim Driscoll
The University of Sydney
Francesco Saverio Violante
IRCCS Azienda Ospedliero-Universitaria di Bologna Policlinico di Sant'Orsola
Mark A. Rubin
University of Bern
Marc Humbert
Inserm
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”